UK Quantum Biomedical Sensing Research Hub
Q-BIOMED
Delivering the quantum-enabled future of early disease diagnosis and treatment
On 26 July, Peter Kyle MP, the Secretary of State for Science, Innovation and Technology announced a major new £24m investment to create a world-leading centre dedicated to health – the Quantum Biomedical Sensing Research Hub.
Q-BIOMED aims to deliver a step change in earlier disease diagnosis and treatment for diseases including cancer and Alzheimer’s disease.
Earlier diagnosis, through ultra-sensitive blood tests, faster MRI scan times, and improved access through lower costs and portable instruments, could offer a paradigm shift in healthcare.
These advances could enable much earlier diagnosis of disease such as cancer allowing for more rapid medical interventions and potentially saving lives. Ultimately, this could translate to better patient outcomes and help to reduce waiting lists, easing pressures on the NHS.
Our Aims
The Q-BIOMED team and our partners
Q-BIOMED, is led by Professor Rachel McKendry (UCL) and Professor Mete Atatüre (University of Cambridge), and brings together six outstanding academic powerhouses (UCL, University of Cambridge, University of Oxford, University of Warwick, Cardiff University, and Heriot-Watt University), working in partnership with six NHS trusts, as well as charities, government, and 17 industry partners.
Q-BIOMED will launch in December 2024.
(Main image left to right): Prof John Morton (Deputy Director, London Centre for Nanotechnology UCL), Prof Rachel McKendry (Co-Director, London Centre for Nanotechnology and Division of Medicine, UCL), Prof Mete Atatüre (Co-Director, Cavendish Laboratory, Cambridge University) and Prof Eleni Nastouli (Consultant virologist Clinical lead Infectious Disease UCLH, and Institute of Child Health UCLH). Credit: James Tye.